Compile Data Set for Download or QSAR
Report error Found 484 Enz. Inhib. hit(s) with all data for entry = 12261
TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485457(N-((1R,2S)-2-Acrylamidocyclohexyl)-4-oxo-5-(5-phen...)
Affinity DataIC50: 2.51nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485461(N-((1R,2S)-2-Acrylamidocyclohexyl)-4-oxo-5-(5- phe...)
Affinity DataIC50: 2.95nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485467(N-((1R,2S)-2-Acrylamidocyclohexyl)-5-(*S)-(2-methy...)
Affinity DataIC50: 3.98nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485459(N-((1R,2S)-2-Acrylamidocyclohexyl)-4-oxo-5-(5-phen...)
Affinity DataIC50: 4.07nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485460(N-((1R,2S)-2-acrylamidocyclopentyl)-4-oxo-5-(5- ph...)
Affinity DataIC50: 4.07nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485458(N-((1RS,2RS)-2-Acrylamidocyclopentyl)-5-(2-methyl-...)
Affinity DataIC50: 4.17nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485600(N-((1R,2S)-2-Acrylamidocyclopentyl)-4-oxo-5-(4-(py...)
Affinity DataIC50: 4.17nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485270(N-((1R,2S)-2-acrylamidocyclopentyl)-4-oxo-5-(4-phe...)
Affinity DataIC50: 4.27nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485345(N-((1R,2S)-2-Acrylamidocyclopentyl)-4-oxo-5-(5-phe...)
Affinity DataIC50: 4.27nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485338(N-((1R,2S)-2-Acrylamidocyclohexyl)-4-oxo-5-(6-phen...)
Affinity DataIC50: 4.47nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485333(N-((1R,2S)-2-Acrylamidocyclopentyl)-4-oxo-5-(6-phe...)
Affinity DataIC50: 4.57nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485367(N-((1R,2S)-2-Acrylamidocyclopentyl)-4-oxo-5-(5-phe...)
Affinity DataIC50: 4.79nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485331(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(*R)-(4-isop...)
Affinity DataIC50: 5.01nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485349(N-((1R,2S)-2-Acrylamidocyclohexyl)-5-(6-cyclobutox...)
Affinity DataIC50: 5.13nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485340(N-((1R,2S)-2-Acrylamidocyclohexyl)-5-(*R)-(4-isopr...)
Affinity DataIC50: 5.25nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485344(N-((1R,2S)-2-Acrylamidocyclopentyl)-4-oxo-5-(6-phe...)
Affinity DataIC50: 5.25nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485464(N-((1R,2S)-2-Acrylamidocyclopentyl)-4-oxo-5-(*S)-(...)
Affinity DataIC50: 5.37nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485335(US10934310, Ex # 197 | N-((1R,2S)-2-Acrylamidocycl...)
Affinity DataIC50: 5.5nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485273(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(*S)-(2-meth...)
Affinity DataIC50: 5.62nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485536(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(*S)-(6-isob...)
Affinity DataIC50: 5.62nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485355(N-((1R,2S)-2-Acrylamidocyclopentyl)-4-oxo-5-(4-phe...)
Affinity DataIC50: 5.89nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485466(N-((1R,2S)-2-Acrylamidocyclohexyl)-4-oxo-5-(2- phe...)
Affinity DataIC50: 5.89nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485534(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(*S)-(6-(cyc...)
Affinity DataIC50: 5.89nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485589(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(*S)-(6-isop...)
Affinity DataIC50: 6.31nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485337(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(*S)-(4-meth...)
Affinity DataIC50: 6.46nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485388(N-((1R,2S)-2-Acrylamidocyclohexyl)-5-(6-isopropoxy...)
Affinity DataIC50: 6.46nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485366(N-((1R,2R)-2-Acrylamidocyclopentyl)-5-(*S)-(4-meth...)
Affinity DataIC50: 6.61nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485593(N-((1S,3R)-3-Acrylamidocyclopentyl)-5-(*S)-(4-meth...)
Affinity DataIC50: 6.76nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485386(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(2-methyl-4-...)
Affinity DataIC50: 6.92nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485332(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(*S)-(4-meth...)
Affinity DataIC50: 7.41nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485365(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(2-methyl-4-...)
Affinity DataIC50: 7.41nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485531(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(2-methyl-4-...)
Affinity DataIC50: 7.41nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485284(N-((1R,2S)-2-Acrylamidocyclohexyl)-4-oxo-5-(4-phen...)
Affinity DataIC50: 7.59nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485271(N-((1R,2R)-2-Acrylamidocyclopentyl)-5-(*S)-(2-meth...)
Affinity DataIC50: 7.76nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485334(N-((1R,2S)-2-Acrylamidocyclohexyl)-4-oxo-5-(2-phen...)
Affinity DataIC50: 7.94nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485359(5-([1,1'-Biphenyl]-3-yl)-N-((1R,2S)-2-acrylamidocy...)
Affinity DataIC50: 8.13nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485462(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(S)-(6-isobu...)
Affinity DataIC50: 8.13nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485529(N-((1R,3S)-3-Acrylamidocyclopentyl)-5-(*S)-(6-(cyc...)
Affinity DataIC50: 8.51nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485284(N-((1R,2S)-2-Acrylamidocyclohexyl)-4-oxo-5-(4-phen...)
Affinity DataIC50: 8.71nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485369(N-((1R,2S)-2-Acrylamidocyclopentyl)-4-oxo-5-(6-phe...)
Affinity DataIC50: 8.71nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485532(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(4-((6-methy...)
Affinity DataIC50: 8.71nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485341(N-((1R,3R)-3-Acrylamidocyclopentyl)-5-(*S)-(2-meth...)
Affinity DataIC50: 8.91nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485522(N-((1R,3S)-3-Acrylamidocyclopentyl)-5-(*S)-(4-meth...)
Affinity DataIC50: 8.91nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485278(5-(*S)-(2-Methyl-4-phenoxyphenyl)-N-((1R,2R)-2-(2-...)
Affinity DataIC50: 9.12nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485470(N-((1*S,3*S)-3-Acrylamidocyclopentyl)-5-(*S)-(4-me...)
Affinity DataIC50: 9.12nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485474(N-((1R,2S)-2-Acrylamidocyclopentyl)-4-oxo-5-(2- ph...)
Affinity DataIC50: 9.12nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485553(5-(*S)-(4-Methyl-6-phenoxypyridin-3-yl)-4-oxo-N-((...)
Affinity DataIC50: 9.12nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485353(N-((1R,2S)-2-Acrylamidocyclohexyl)-5-(6-cyclobutox...)
Affinity DataIC50: 9.33nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485339(N-((1R,2S)-2-Acrylamidocyclohexyl)-5-(*S)-(4-methy...)
Affinity DataIC50: 9.55nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485601(N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(3-isopropyl...)
Affinity DataIC50: 9.55nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 484 total ) | Next | Last >>
Jump to: